Muscle Relaxant Drugs Market
授權報價
| Single User License | $4,500 USD |
| Multiple User License | $5,500 USD |
| Custom Research License | $8,000 USD |
完整報告名稱與涵蓋範圍
Muscle Relaxant Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type (Skeletal Muscle Relaxant Drugs, Facial Muscle Relaxant Drugs, Neuromuscular Blocking Agents), By Route of Administration (Oral, Injectable, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region & Competition, 2021-2031F
報告摘要
Market Overview
The global muscle relaxant drugs market is projected to expand from USD 4.15 Billion in 2025 to USD 5.38 Billion by 2031, exhibiting a 4.42% Compound Annual Growth Rate. These pharmaceutical agents are formulated to alleviate muscle spasms and spasticity by targeting nerve signals in the central nervous system or directly acting on skeletal muscle fibers. This market expansion is primarily driven by the rising incidence of musculoskeletal disorders and an aging global population prone to chronic pain conditions, with nearly half of arthritis sufferers reporting activity limitations in 2025, highlighting the critical need for effective interventions. However, the market's growth is moderated by substantial challenges concerning the safety profile of these medications, including risks of sedation, dependency, and potential abuse, especially with centrally acting agents. Such concerns have led to rigorous regulatory oversight and cautious prescribing practices, which pose a significant obstacle to the broader market expansion.
Market Driver
The increasing prevalence of chronic musculoskeletal and neurological disorders serves as a key driver for the global muscle relaxant drugs market. Conditions like low back pain, affecting approximately 628.8 million people globally in 2021, multiple sclerosis, and cerebral palsy, generate persistent muscle spasms that necessitate long-term pharmacological treatment to enhance patient mobility and quality of life, thereby creating a sustained demand for effective antispasmodic agents. Concurrently, the rapid growth of the global geriatric population, projected to reach 2.2 billion by the late 2070s, substantially boosts market expansion due to their increased susceptibility to age-related musculoskeletal injuries and spasticity, ensuring consistent prescription volumes for these therapeutics. Furthermore, the evolving landscape of pain management, favoring alternatives to narcotics, also reinforces this growth; opioid prescriptions have notably decreased by 51.7% since 2012, positioning muscle relaxants as crucial elements in contemporary non-opioid pain relief strategies.
Market Challenge
Safety concerns regarding the adverse effect profile and potential for abuse associated with muscle relaxants represent a significant impediment to global market growth. Centrally acting muscle relaxants frequently cause side effects such as sedation, dizziness, and carry a considerable risk of physical dependency, leading to strict regulatory oversight and restrictive prescribing guidelines from healthcare institutions. This caution among physicians results in shorter treatment durations and reluctance to prescribe these drugs for chronic pain management, directly limiting the patient pool and hindering market capitalization on the rising prevalence of musculoskeletal conditions. Further exacerbating this challenge is the widespread misuse of prescription medications, with an estimated 13.8 million individuals annually misusing them in 2025, including muscle relaxants, which reinforces the need for vigilance and consequently restraints market revenue and prescription volume expansion.
Market Trends
The market is undergoing transformation due to the increasing adoption of long-acting botulinum toxin formulations, driven by a demand for prolonged aesthetic and therapeutic effects with reduced injection frequency. Liquid-formulation toxins, offering superior convenience and precision for conditions such as cervical dystonia and glabellar lines, are gaining prominence over conventional powder-based alternatives; Galderma's neuromodulator net sales reaching USD 1,285 million in 2024 exemplify the rapid embrace of these advanced biologics. Concurrently, the development of cannabinoid-based spasmolytics signifies a crucial evolution in spasticity management, especially for patients unresponsive to traditional antispasmodics. This trend reflects a broader industry shift towards non-opioid, neuromodulatory interventions for chronic neurological disorders like multiple sclerosis, with regulatory approvals and commercial availability of oromucosal spray formulations, such as Sativex which recorded approximately USD 18.9 million in net product sales for 2024, validating this therapeutic class as a valuable adjunct to standard care.
Key Market Players
* Amneal Pharmaceuticals LLC
* Ipsen Biopharmaceuticals Inc
* Merz Pharmaceuticals LLC
* Par Pharmaceutical Inc
* Endo Pharmaceuticals Inc
* Vertical Pharmaceuticals Inc
* Mallinckrodt LLC
* Sterix Ltd
* Eisai Co Ltd
* Teva Pharmaceuticals USA Inc
Report Scope
In this report, the Global Muscle Relaxant Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
# Muscle Relaxant Drugs Market, By Drug Type
* Skeletal Muscle Relaxant Drugs
* Facial Muscle Relaxant Drugs
* Neuromuscular Blocking Agents
# Muscle Relaxant Drugs Market, By Route of Administration
* Oral
* Injectable
* Others
# Muscle Relaxant Drugs Market, By Distribution Channel
* Hospital Pharmacies
* Retail Pharmacies
* Online Pharmacies
# Muscle Relaxant Drugs Market, By Region
* North America
United States
Canada
Mexico
* Europe
France
United Kingdom
Italy
Germany
Spain
* Asia Pacific
China
India
Japan
Australia
South Korea
* South America
Brazil
Argentina
Colombia
* Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Muscle Relaxant Drugs Market.
Available Customizations:
Global Muscle Relaxant Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
* Detailed analysis and profiling of additional market players (up to five).
目錄 Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Muscle Relaxant Drugs Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug Type (Skeletal Muscle Relaxant Drugs, Facial Muscle Relaxant Drugs, Neuromuscular Blocking Agents)
5.2.2. By Route of Administration (Oral, Injectable, Others)
5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
5.2.4. By Region
5.2.5. By Company (2025)
5.3. Market Map
6. North America Muscle Relaxant Drugs Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Type
6.2.2. By Route of Administration
6.2.3. By Distribution Channel
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Muscle Relaxant Drugs Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug Type
6.3.1.2.2. By Route of Administration
6.3.1.2.3. By Distribution Channel
6.3.2. Canada Muscle Relaxant Drugs Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug Type
6.3.2.2.2. By Route of Administration
6.3.2.2.3. By Distribution Channel
6.3.3. Mexico Muscle Relaxant Drugs Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug Type
6.3.3.2.2. By Route of Administration
6.3.3.2.3. By Distribution Channel
7. Europe Muscle Relaxant Drugs Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Type
7.2.2. By Route of Administration
7.2.3. By Distribution Channel
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Muscle Relaxant Drugs Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Type
7.3.1.2.2. By Route of Administration
7.3.1.2.3. By Distribution Channel
7.3.2. France Muscle Relaxant Drugs Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Type
7.3.2.2.2. By Route of Administration
7.3.2.2.3. By Distribution Channel
7.3.3. United Kingdom Muscle Relaxant Drugs Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Type
7.3.3.2.2. By Route of Administration
7.3.3.2.3. By Distribution Channel
7.3.4. Italy Muscle Relaxant Drugs Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Drug Type
7.3.4.2.2. By Route of Administration
7.3.4.2.3. By Distribution Channel
7.3.5. Spain Muscle Relaxant Drugs Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Drug Type
7.3.5.2.2. By Route of Administration
7.3.5.2.3. By Distribution Channel
8. Asia Pacific Muscle Relaxant Drugs Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Type
8.2.2. By Route of Administration
8.2.3. By Distribution Channel
8.2.4. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Muscle Relaxant Drugs Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Type
8.3.1.2.2. By Route of Administration
8.3.1.2.3. By Distribution Channel
8.3.2. India Muscle Relaxant Drugs Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Type
8.3.2.2.2. By Route of Administration
8.3.2.2.3. By Distribution Channel
8.3.3. Japan Muscle Relaxant Drugs Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Type
8.3.3.2.2. By Route of Administration
8.3.3.2.3. By Distribution Channel
8.3.4. South Korea Muscle Relaxant Drugs Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug Type
8.3.4.2.2. By Route of Administration
8.3.4.2.3. By Distribution Channel
8.3.5. Australia Muscle Relaxant Drugs Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug Type
8.3.5.2.2. By Route of Administration
8.3.5.2.3. By Distribution Channel
9. Middle East & Africa Muscle Relaxant Drugs Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Type
9.2.2. By Route of Administration
9.2.3. By Distribution Channel
9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Muscle Relaxant Drugs Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Type
9.3.1.2.2. By Route of Administration
9.3.1.2.3. By Distribution Channel
9.3.2. UAE Muscle Relaxant Drugs Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Type
9.3.2.2.2. By Route of Administration
9.3.2.2.3. By Distribution Channel
9.3.3. South Africa Muscle Relaxant Drugs Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Type
9.3.3.2.2. By Route of Administration
9.3.3.2.3. By Distribution Channel
10. South America Muscle Relaxant Drugs Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug Type
10.2.2. By Route of Administration
10.2.3. By Distribution Channel
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Muscle Relaxant Drugs Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug Type
10.3.1.2.2. By Route of Administration
10.3.1.2.3. By Distribution Channel
10.3.2. Colombia Muscle Relaxant Drugs Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug Type
10.3.2.2.2. By Route of Administration
10.3.2.2.3. By Distribution Channel
10.3.3. Argentina Muscle Relaxant Drugs Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drug Type
10.3.3.2.2. By Route of Administration
10.3.3.2.3. By Distribution Channel
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Muscle Relaxant Drugs Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Amneal Pharmaceuticals LLC
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Ipsen Biopharmaceuticals Inc
15.3. Merz Pharmaceuticals LLC
15.4. Par Pharmaceutical Inc
15.5. Endo Pharmaceuticals Inc
15.6. Vertical Pharmaceuticals Inc
15.7. Mallinckrodt LLC
15.8. Sterix Ltd
15.9. Eisai Co Ltd
15.10. Teva Pharmaceuticals USA Inc
16. Strategic Recommendations
17. About Us & Disclaimer
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 TechSci Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們